Mar 28th, 2024
Merck CEO on Winrevair Approval, Obesity Drug, Health Costs
Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure. Speaking on Bloomberg Television, Davis also comments on Merck's development of an obesity-fighting drug and health-care costs. (Video edited to remove incorrect graphic.)
